Brief: Organovo Announces Positive Phase 2 Results for FXR314

VivoSim Labs

15/04/2024 13:30

April 15 (Reuters) - Organovo Holdings Inc  ONVO.O :
    * ORGANOVO ANNOUNCES POSITIVE PHASE 2 RESULTS FOR FXR314 IN
METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) SHOWING
BOTH REDUCTION IN LIVER FAT CONTENT AND STRONG SAFETY AND
TOLERABILITY COMPARED TO PLACEBO
    * ORGANOVO HOLDINGS INC - FXR314 WAS ALSO FOUND TO BE SAFE
AND
WELL TOLERATED
    * ORGANOVO HOLDINGS:STUDY SHOWED STATISTICALLY SIGNIFICANT
REDUCTION IN LIVER FAT CONTENT FROM BASELINE IN PATIENTS
RECEIVING FXR314 COMPARED TO PLACEBO
    * ORGANOVO HOLDINGS-STUDY RESULTS SHOWED STATISTICALLY
SIGNIFICANT
REDUCTION IN LIVER FAT CONTENT FROM BASELINE IN PATIENTS
RECEIVING FXR314 VERSUS PLACEBO
    * ORGANOVO HOLDINGS INC: TREATMENT-EMERGENT ADVERSE EVENTS
WERE
MOSTLY MILD TO MODERATE IN SEVERITY

Source text for Eikon:  ID:nGNX661Khz 
Further company coverage:  ONVO.O 

 ((Reuters.Briefs@thomsonreuters.com;))